Clinical trials: Demyelinating Disorder
Multiple Sclerosis, Relapsing-Remitting
Tecfidera and the Gut Microbiota
The primary objective of the study is to determine if dimethyl fumarate (DMF) causes changes in the abundance and diversity of commensal microbiota.
- Trial name
- TECONGUT (NCT02471560)
- Testing
- dimethyl fumarate, injectable MS DMT
- Where
- 7 sites in Norway
- Volunteers
- 36 people
- Sponsor
- Biogen
Neuromyelitis Optica
In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO
This is a fundamental, prospective, multi-centres, interventional non-comparative study without the administration of a study product to patients.
- Trial name
- NCT04629274
- Testing
- Blood sampling
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- Imcyse SA
Multiple Sclerosis, Relapsing Forms
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ascending intravenous (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of multiple sclerosis (MS).
- Trial name
- NCT01585766
- Testing
- MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, MEDI-551 100 MG-IV
- Where
- 16 sites in United States, Poland and 2 more
- Volunteers
- 56 people
- Sponsor
- MedImmune LLC
Multiple Sclerosis
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
The primary objective is to assess the pharmacokinetic (PK) profile of natalizumab (Tysabri) at steady state. The secondary objective is to assess the pharmacodynamics (PD) profile (α4 integrin saturation) of Tysabri at steady…
- Trial name
- NCT00744679
- Testing
- Natalizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
- Trial name
- NCT00030966
- Testing
- Natalizumab
- Where
- 88 sites in United States, Austria and 5 more
- Volunteers
- 1,200 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
The purpose of this study is to determine if BHT-3009 decreases inflammation (measured by gadolinium enhancing MRI lesions) in the brains of people with relapsing remitting multiple sclerosis.
- Trial name
- NCT00382629
- Testing
- BHT-3009 0.5 mg, BHT-3009 1.5 mg
- Volunteers
- 252 people
- Sponsor
- Bayhill Therapeutics
Multiple Sclerosis
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An open-label extension study in which patients with multiple sclerosis received GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] for four weeks in an open-label manner.
- Trial name
- NCT01610713
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 154 people
- Sponsor
- Jazz Pharmaceuticals
Neuromyelitis Optica Spectrum Disorders
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Neuromyelitis Optica Spectrum Disorders.
- Trial name
- NCT03330418
- Testing
- RC18 160 mg
- Where
- China
- Volunteers
- 178 people
- Sponsor
- RemeGen Co., Ltd.
Multiple Sclerosis
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
- Trial name
- NCT06433765
- Testing
- No intervention
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression…
- Trial name
- Cognition (NCT01333501)
- Testing
- Fingolimod, Interferon beta 1b
- Where
- 26 sites in Germany, Italy
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
The MS pilot study will assess the safety and investigate the remyelinating effects of the SetPoint System (study device) in adult patients diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT06796504
- Testing
- Implant Procedure, Disease-Modifying Therapies (DMTs), Active stimulation
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- SetPoint Medical Corporation
Multiple Sclerosis
Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers
The primary objective of the study is to compare in healthy subjects, the GI tolerability of bioequivalent doses of Bafiertam™(monomethyl fumarate) and its pro-drug Tecfidera® (dimethyl fumarate).
- Trial name
- NCT04022473
- Testing
- Bafiertam, Tecfidera
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Multiple Sclerosis
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
- Trial name
- NCT01359566
- Testing
- Arbaclofen placarbil 15 mg BID, Arbaclofen placarbil 30 mg BID, Arbaclofen placarbil 45 mg BID
- Where
- 28 sites in United States
- Volunteers
- 228 people
- Sponsor
- XenoPort, Inc.
Systemic Lupus Erythematosus, Sjogren's Syndrome
Cell Surface Marker Expression in Autoimmune Diseases
This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's…
- Conditions
- Systemic Lupus Erythematosus, Sjogren's Syndrome, Multiple Sclerosis, Systemic Sclerosis
- Trial name
- CASCADE (NCT03757065)
- Where
- 2 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Alpine Immune Sciences, Inc.
Multiple Sclerosis
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
The purpose of this observational study is to collect long-term data on safety and effectiveness of fingolimod, particularly including clinical disease and patient outcome related parameters such as relapse and disability, in…
- Trial name
- NCT01281657
- Testing
- fingolimod
- Where
- 58 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Novartis
Autoimmune Diseases, Ulcerative Colitis
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation.
- Conditions
- Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma
- Trial name
- NCT06587828
- Testing
- Companion blood samples with procedure
- Where
- 11 sites in United States
- Volunteers
- 238 people
- Sponsor
- TScan Therapeutics, Inc.
Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod…
- Trial name
- SWISSMASIA (NCT04895202)
- Testing
- Siponimod
- Where
- 6 sites in Switzerland
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Pelizaeus-Merzbacher Disease
Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease
The purpose of the study is to prospectively assess longitudinal changes in proteolipid protein 1 (PLP1) protein, disease-related biomarkers in cerebral spinal fluid (CSF) and blood, neuroimaging parameters relevant to…
- Trial name
- NCT05659901
- Where
- 10 sites in United States, France and 5 more
- Volunteers
- 32 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Multiple Sclerosis
Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)
SB-683699 is an oral medication that is thought to reduce the number of active white blood cells entering the brain; these white blood cells are part of the disease process for MS.
- Trial name
- NCT00395317
- Testing
- Firategrast 150 mg, Firategrast 300 mg
- Where
- 79 sites in Australia, Austria and 12 more
- Volunteers
- 343 people
- Sponsor
- GlaxoSmithKline
Group B Streptococcus
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women
This study will evaluate the safety and immunogenicity of a Group B Streptococcus vaccine.
- Trial name
- NCT01150123
- Testing
- Group B streptococcus (GBS) vaccine- low dose, Group B streptococcus (GBS) vaccine- High dose
- Where
- Belgium
- Volunteers
- 678 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.